Omeros (OMER) Said Symptoms Subscale of the KOOS for OMS103HP Did Not Reach Statistical Significance
Tweet Send to a Friend
Omeros Corporation (NASDAQ: OMER) reported results from its first pivotal Phase 3 clinical trial evaluating OMS103HP in patients undergoing arthroscopic ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
